Skip to Content

Tecentriq Dosage

Generic name: atezolizumab 1200mg in 20mL
Dosage form: injection, solution

Medically reviewed on March 22, 2018.

Recommended Dosing

The recommended dose of TECENTRIQ is 1200 mg administered as an intravenous infusion over 60 minutes every 3 weeks until disease progression or unacceptable toxicity. If the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes. Do not administer TECENTRIQ as an intravenous push or bolus.

Dose Modifications

No dose reductions of TECENTRIQ are recommended.

Withhold TECENTRIQ for any of the following:

TECENTRIQ may be resumed in patients whose adverse reactions recover to Grade 0–1.

Permanently discontinue TECENTRIQ for any of the following:

Preparation and Administration


Visually inspect drug product for particulate matter and discoloration prior to administration whenever solution and container permit. TECENTRIQ is a colorless to slightly yellow solution. Discard the vial if the solution is cloudy, discolored, or visible particles are observed. Do not shake the vial.

Prepare the solution for infusion as follows:

  • Withdraw 20 mL of TECENTRIQ from the vial.
  • Dilute into a 250 mL polyvinyl chloride (PVC), polyethylene (PE), or polyolefin (PO) infusion bag containing 0.9% Sodium Chloride Injection, USP.
  • Dilute with 0.9% Sodium Chloride Injection only.
  • Mix diluted solution by gentle inversion. Do not shake.
  • Discard used or empty vials of TECENTRIQ.

Storage of Infusion Solution

This product does not contain a preservative.

Administer immediately once prepared. If diluted TECENTRIQ infusion solution is not used immediately, it can be stored either:

  • At room temperature for no more than 6 hours from the time of preparation. This includes room temperature storage of the infusion in the infusion bag and time for administration for infusion.
  • Under refrigeration at 2°C–8°C (36°F–46°F) for no more than 24 hours.

Do not freeze.

Do not shake.


Administer the initial infusion over 60 minutes through an intravenous line with or without a sterile, non-pyrogenic, low-protein binding in-line filter (pore size of 0.2–0.22 micron). If the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes.

Do not co-administer other drugs through the same intravenous line.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.